鲍氏不动杆菌耐药性分析

Drug resistance of acinetobacter baumannii

目的探讨鲍氏不动杆菌的临床分布及耐药性,指导临床合理用药。方法回顾性分析医院2007-2009年分离的664株鲍氏不动杆菌药物耐药性试验资料。结果 2007-2009年临床分离的5851株病原菌中,共检出664株鲍氏不动杆菌,检出率为11.35%,其中2007年检出142株,检出率8.41%,2008年175株,检出率11.32%,2009年347株,检出率13.26%;分离率居前3位的临床科室依次为ICU、呼吸内科、神经内科;鲍氏不动杆菌对头孢哌酮/舒巴坦、亚胺培南、美罗培南耐药率分别为14.01%、20.78%、21.23%,泛耐药菌株占7.68%。结论鲍氏不动杆菌耐药率高,应合理使用抗菌药物,加强鲍氏不动杆菌耐药性的监测与控制,预防鲍氏不动杆菌医院感染发生。

OBJECTIVE To approach the clinical distribution and drug resistance of Acinetobacter baumannii（ABA） to instruct clinical application of the antibiotics.METHODS The clinical data of drug sensitivity test of 664 ABA strains from 2007 to 2009 were analyzed retrospectively.RESULTS Of 5851 strains of pathogens isolated from 2007 to 2009,a total of 664 ABA strains were detected with the detection rate of 11.35%,among which,142 strains were detected in 2007 with the detection rate of 8.41%,175 strains in 2008 with 11.32% and 347 strains in 2009 with 13.26%.The top three departments were the intensive care unit,department respiratory medicine and department of neurology.The resistance rates to cefoperazone/sulbactam,imipenem and meropenem were 14.01%,20.78% and 21.23%,respectively,and pan-resistant strains accounted for 7.68%.CONCLUSION The drug resistance rate of ABA is high.It should use antibiotics reasonably,strengthen the monitoring and controlling of drug resistance of ABA and prevent ABA infection.